

Immune Checkpoint Inhibitor Nivolumab for Patients with Rare CNS Cancers

A study for adults with central nervous system (CNS) cancers.



+ Objective

National Cancer Institute (NCI) researchers are conducting a study of patients with CNS cancers.

This study will test whether stimulating the immune system using the drug nivolumab can shrink brain or spine tumors or increase the time it takes for them to grow or spread.

clinicaltrials.gov ID: NCT03173950

What the study involves:

- Full physical and neurological examination
- Health and symptoms questionnaire
- MRIs and neurological function tests
- Study of tumor tissue from prior surgeries
- Receive drug nivolumab for up to 20 treatments over 64 weeks
- Your samples used for genetic testing
- Monitoring for up to 5 years after treatment
- All tests, procedures and medications provided at no cost
- Compensation may be provided

You can participate if you:

- Are age 18 or older
- Are diagnosed with recurring CNS tumors
- Do not have hepatitis
- Are not pregnant or breastfeeding

You can participate in this study by visiting the NIH at Bethesda, Maryland for a clinical assessment.

Questions?

Contact us at (240) 760-6010 or NCINOBReferrals@mail.nih.gov



Tumor Types Include:

- Atypical Teratoid Rhabdoid Tumor (ATRT)
- Choroid Plexus Tumors (Carcinoma, Papilloma, Atypical Papilloma)
- Ependymoma
- Gliomatosis Cerebri
- Gliosarcoma or Primary CNS Sarcoma
- Histone Mutated Glioma
- Medulloblastoma
- Meningioma (High Grade)
- Pineal Region Tumors (Pineoblastoma, Pineocytoma, PTID, PTPR)
- Pleomorphic Xanthoastrocytoma (PXA) and Anaplastic Pleomorphic Xanthoastrocytoma (APXA)
- Primitive Neuroectodermal Tumors (PNET)